Drug Type Aptamers |
Synonyms NOX-D21, NOXD14, NOXD19 + [2] |
Target |
Action antagonists, inhibitors |
Mechanism C5AR1 antagonists(C5a anaphylatoxin chemotactic receptor antagonists), C5a inhibitors(complement C5a inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Preclinical | Japan | 01 May 2017 | |
Muscular Dystrophy, Duchenne | Preclinical | Germany | 01 May 2017 | |
Diabetes Mellitus | Preclinical | Germany | - | |
Inflammation | Preclinical | Germany | - | |
Neoplasms | Preclinical | Germany | - | |
Pain | Preclinical | Germany | - | |
Pneumonia | Preclinical | Germany | - | |
Sepsis | Preclinical | Spain | - |